Sign in or create an account to add this stock to your watchlist.
About Rhythm Pharmaceuticals (NASDAQ:RYTM)
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280
Debt
Debt-to-Equity RatioN/A
Current Ratio24.85
Quick Ratio24.85
Price-To-Earnings
Trailing P/E Ratio-10.70
Forward P/E Ratio-16.46
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.85 per share
Price / Book6.24
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees26
Outstanding Shares27,530,000
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced its quarterly earnings results on Monday, May, 14th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.15. View Rhythm Pharmaceuticals' Earnings History.
What price target have analysts set for RYTM?
4 brokerages have issued 1-year price targets for Rhythm Pharmaceuticals' shares. Their predictions range from $23.00 to $40.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $31.25 in the next twelve months. View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (5/23/2018)
- 2. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018)
- 3. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Tesaro (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Exec. Director (Age 64)
- Dr. Fred T. Fiedorek M.D., Chief Medical Officer (Age 63)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 49)
- Mr. Leonardus H.T. van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 39)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
When did Rhythm Pharmaceuticals' lock-up period expire?
Rhythm Pharmaceuticals' lock-up period expired on Tuesday, April 3rd. Rhythm Pharmaceuticals had issued 7,050,000 shares in its public offering on October 5th. The total size of the offering was $119,850,000 based on an initial share price of $17.00. Since the end of Rhythm Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Rhythm Pharmaceuticals been receiving favorable news coverage?
News headlines about RYTM stock have trended positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 0.33 on Accern's scale. They also assigned news articles about the company an impact score of 45.35 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Rhythm Pharmaceuticals' major shareholders?
Rhythm Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.40%), Foresite Capital Management IV LLC (0.73%), Point72 Asset Management L.P. (0.65%), JPMorgan Chase & Co. (0.57%), Franklin Resources Inc. (0.39%) and Northern Trust Corp (0.33%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, James E Flynn, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.
Which institutional investors are selling Rhythm Pharmaceuticals stock?
Which institutional investors are buying Rhythm Pharmaceuticals stock?
RYTM stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Russell Investments Group Ltd., JPMorgan Chase & Co., Alps Advisors Inc., BlackRock Inc., Foresite Capital Management IV LLC and Northern Trust Corp. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $30.28.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $836.92 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe.
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (RYTM)
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Rhythm Pharmaceuticals in the last 12 months. Their average twelve-month price target is $31.25, suggesting that the stock has a possible upside of 3.20%. The high price target for RYTM is $40.00 and the low price target for RYTM is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $31.25 | $31.25 | $31.25 | $31.25 |
| Price Target Upside: | 3.20% upside | 13.18% upside | 22.74% upside | 22.74% upside |
Rhythm Pharmaceuticals (NASDAQ:RYTM) Consensus Price Target History
Rhythm Pharmaceuticals (NASDAQ:RYTM) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Rhythm Pharmaceuticals (NASDAQ:RYTM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 88.24%
Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/21/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 131,636 | $30.88 | $4,064,919.68 | |  |
| 10/10/2017 | David P Meeker | Director | Buy | 25,000 | $17.00 | $425,000.00 | | |
| 10/10/2017 | James E Flynn | Insider | Buy | 355,000 | $17.00 | $6,035,000.00 | | |
| 10/10/2017 | S.A. Ipsen | Major Shareholder | Buy | 20,000 | $17.00 | $340,000.00 | | |
| 10/5/2017 | Bros. Advisors Lp Baker | Insider | Buy | 885,000 | $17.00 | $15,045,000.00 | | |
(Data available from 1/1/2013 forward)
Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines
| Source: |
|
Rhythm Pharmaceuticals (NASDAQ:RYTM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Income Statement, Balance Sheet and Cash Flow Statement
Rhythm Pharmaceuticals (NASDAQ RYTM) Stock Chart for Friday, May, 25, 2018
Loading chart…
